

## **Product datasheet for TL312092V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ITGA7 Human shRNA Lentiviral Particle (Locus ID 3679)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ITGA7 Human shRNA Lentiviral Particle (Locus ID 3679)

**Locus ID:** 3679

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ITGA7 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 001144996, NM 001144997, NM 002206, NM 002206.1, NM 002206.2, NM 001144997.1,

BC050280, BC050280.1, NM 001367993, NM 001367994, NM 001144996.2, NM 002206.3

UniProt ID: Q13683

**Summary:** The protein encoded by this gene belongs to the integrin alpha chain family. Integrins are

heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. They mediate a wide spectrum of cell-cell and cell-matrix interactions, and thus play a role in cell migration, morphologic development, differentiation, and metastasis. This protein

functions as a receptor for the basement membrane protein laminin-1. It is mainly expressed

in skeletal and cardiac muscles and may be involved in differentiation and migration

processes during myogenesis. Defects in this gene are associated with congenital myopathy. Alternatively spliced transcript variants encoding different isoforms have been noted for this

gene. [provided by RefSeq, Feb 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).